Group 1 - The total number of shares representing the share capital as of December 31, 2025, is 390,202,580 [1] - The gross total of voting rights is reported as 12,704,596 [1] - The net total of voting rights, which accounts for shares with no voting rights, is 12,691,760 [1] Group 2 - The company is listed on Euronext Paris under the ISIN code FR0000031577 [2] - The company specializes in animal health, indicating a focus on veterinary products and services [2]

Core Insights - ImmuCell estimates the worldwide total addressable market for scour protection at approximately $900 million [1] - The company is shifting its strategy to focus on the First Defense calf-health franchise while pausing investment in Re-Tain due to an FDA "Incomplete Letter" [6][5] Market Dynamics - Management highlighted that the economics of newborn calves have changed significantly, with calf values rising from about $200 in 2003 to approximately $1,300 today, leading to increased demand for scour protection [2] - Calf sales have grown from 2%-3% to 20%-25% of annual dairy income for some operations [2] Strategic Shift - ImmuCell plans to complete ongoing investigational studies for Re-Tain by 2026 and will focus on expanding First Defense capacity instead [3] - The decision to pause investment in Re-Tain is based on confidence in First Defense's growth potential and the implications of the FDA's Incomplete Letter [5] Financial Performance - Unaudited product sales for Q4 2025 were reported at $7.6 million, a decrease of 1.6% from Q4 2024, with domestic sales growing 8.7% year-over-year [8][9] - Total product sales for the full year 2025 increased by 4.3% to $27.6 million, with a noted shift towards the Tri-Shield product within the First Defense suite [10] Manufacturing and Compliance Issues - ImmuCell has passed FDA requirements for safety and efficacy for Re-Tain, but issues with the contract manufacturer responsible for aseptic filling have delayed approval [12][13] - The company plans to repurpose most manufacturing assets from Re-Tain for First Defense, although certain equipment will not be useful [16] Future Plans and Investments - The company is expanding its sales team by 50% and creating two new U.S. territories to enhance commercial expansion [19] - Management anticipates a non-cash impairment write-down of approximately $2.9 million related to Re-Tain, along with an estimated inventory write-down of about $600,000 [17][18] - Additional capital may be needed for future investments, including a potential $3 million capital outlay for a new freeze dryer [20]

Core Viewpoint - ImmuCell Corporation reported preliminary, unaudited sales results for Q4 and full year 2025, indicating a mixed performance with a slight decline in quarterly sales but an overall increase in annual sales [1][3]. Sales Performance - Total sales for Q4 2025 were $7.6 million, a 1.6% decline from $7.8 million in Q4 2024 [3]. - Total sales for the full year 2025 reached $27.6 million, representing a 4.3% increase compared to $26.5 million in 2024 [3]. - Domestic sales for Q4 2025 were $7.0 million, an 8.7% increase from $6.4 million in Q4 2024 [5]. - International sales for Q4 2025 were $0.6 million, a significant decline of 52.6% from $1.3 million in Q4 2024 [5]. Product Line Performance - Tri-Shield sales for Q4 2025 were $6.0 million, a 41.3% increase from $4.2 million in Q4 2024 [5]. - Dual-Force and other sales for Q4 2025 were $1.7 million, a 53.0% decline from $3.6 million in Q4 2024 [5]. - For the full year 2025, Tri-Shield sales totaled $19.9 million, a 26.5% increase from $15.8 million in 2024 [5]. - Dual-Force sales for the full year 2025 were $6.9 million, a 27.4% decline from $9.6 million in 2024 [5]. Strategic Focus - The company announced a strategic shift to focus on expanding the First Defense product line after receiving an FDA Incomplete Letter for the Re-Tain product [3][6]. - ImmuCell plans to repurpose assets related to Re-Tain, valued at approximately $15.5 million, to enhance the First Defense product line [3][4]. - Manufacturing improvements have increased output of the lyophilization process by over 15% year-over-year in 2025, with plans for similar enhancements in 2026 [4]. Financial Write-Downs - The company expects to record a non-cash impairment write-down of approximately $2.9 million related to Re-Tain during Q4 2025 [3][4]. - Additional write-downs include $0.1 million for other property, plant, and equipment, and $0.6 million for inventory deemed unfit for processing [4].

Core Viewpoint - ImmuCell Corporation is shifting its strategic focus towards the First Defense product line and away from Re-Tain, with upcoming discussions on its unaudited sales results for 2025 [2][3]. Group 1: Strategic Changes - The company announced a strategic change in focus towards the First Defense product line on December 24, 2025 [2]. - The upcoming conference call on January 9, 2026, will address this strategic shift and the unaudited topline sales results for the fourth quarter and full year ended December 31, 2025 [3]. Group 2: Financial Results and Conference Calls - ImmuCell plans to release its full unaudited financial results for the quarter and year ended December 31, 2025, after the market closes on February 25, 2026 [4]. - A conference call to discuss these financial results is scheduled for February 26, 2026, at 9:00 AM ET [4]. Group 3: Company Overview - ImmuCell Corporation focuses on creating scientifically proven products that enhance cattle health and productivity, specifically through its First Defense product, which provides Immediate Immunity™ to newborn dairy and beef calves [5].

Core Viewpoint - Elanco Animal Health Incorporated will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with key executives representing the company [1]. Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovating and delivering products and services for the prevention and treatment of diseases in farm animals and pets [3]. - The company has a 70-year heritage in animal health and aims to create value for farmers, pet owners, veterinarians, stakeholders, and society [3]. - Elanco's vision is centered around "Food and Companionship Enriching Life," with a commitment to making a meaningful impact on local and global communities [3]. Event Details - The conference will feature a live audio webcast available in the "Events and Presentations" section of Elanco's investor website, with a replay accessible for a limited time after the event [2].

Group 1: RenaissanceRe (RNR) - RenaissanceRe provides property-catastrophe reinsurance globally on an excess of loss basis [1] - The company has a Zacks Rank 1 (Strong Buy) and a Growth Score of A [2] - The Zacks Consensus Estimate for its current year earnings has increased by 12.9% over the last 60 days [1] Group 2: Great Lakes Dredge & Dock (GLDD) - Great Lakes Dredge & Dock is the largest provider of dredging services in the US [2] - The company also holds a Zacks Rank 1 and a Growth Score of A [3] - The Zacks Consensus Estimate for its current year earnings has increased by 6.9% over the last 60 days [2] Group 3: Phibro Animal Health (PAHC) - Phibro Animal Health is a leading global diversified animal health and mineral nutrition company [3] - The company carries a Zacks Rank 1 and has a Growth Score of B [4] - The Zacks Consensus Estimate for its current year earnings has increased by 9.1% over the last 60 days [3]

Core Insights - Zoetis Inc. (NYSE:ZTS) has been recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - BofA downgraded Zoetis from Buy to Neutral and reduced its price target from $165 to $135 [2] - Health Canada approved Portela™ (relfovetmab injection) for osteoarthritis pain relief in cats, which is expected to be commercially available in Canada and the EU by 2026 [3][4] Product Development - Portela is designed to provide up to three months of pain relief from osteoarthritis with a single injection, targeting anti-nerve growth factor (NGF) [3] - A nine-month field trial in Europe demonstrated Portela's effectiveness in reducing OA pain and its tolerability in cats, including those with kidney disease [4] - The approval of Portela signifies Zoetis's commitment to developing innovative therapies for companion animals, adding to its existing OA pain treatment portfolio [5] Company Positioning - Zoetis is the largest global animal health company, focusing on advancing animal care worldwide [6] - Despite the potential of Zoetis as an investment, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [6]

Core Viewpoint - Zoetis Inc. will host a webcast and conference call to discuss its fourth quarter and full year 2025 financial results on February 12, 2026, led by CEO Kristin Peck and CFO Wetteny Joseph [1]. Group 1: Financial Results Announcement - The conference call is scheduled for 8:30 a.m. (ET) on February 12, 2026, where financial analysts will have the opportunity to ask questions [1]. - Investors and the public can access the live webcast through the Zoetis website, with pre-registration available starting today [2]. Group 2: Company Overview - Zoetis is recognized as the world's leading animal health company, focusing on advancing care for animals and supporting those who raise and care for them [3]. - The company has a strong portfolio and pipeline of medicines, vaccines, diagnostics, and technologies, impacting over 100 countries [3]. - In 2024, Zoetis generated revenue of $9.3 billion and employs approximately 13,800 people [3].

Core Viewpoint - Zomedica Corp. has launched the VETGuardian PLUS monitor, enhancing its Zero Touch™ patient monitoring platform for veterinary clinics, aimed at improving workflow efficiency and clinical confidence while supporting long-term growth strategy [1] Group 1: Product Launch - The VETGuardian PLUS monitor is the next generation of the original VETGuardian® system [1] - New features have been added to improve ease of use and access to patient data [1] Group 2: Company Strategy - The launch of the VETGuardian PLUS monitor aligns with Zomedica's long-term growth strategy [1] - The product aims to strengthen clinical confidence in veterinary practices [1]

Group 1 - Zoetis Inc. is recognized as one of the 15 Dividend Stocks with low payout ratios and strong upside potential [1] - Morgan Stanley has lowered its price target for Zoetis to $160 from $175 while maintaining an Overweight rating, highlighting the attractive opportunities in healthcare technology and providers for 2026 [2] - Zoetis received regulatory approval from Health Canada for Portela™ (relfovetmab injection), a treatment for osteoarthritis pain in cats, which provides three months of pain relief with a single injection [3][4] Group 2 - Clinical studies demonstrated that Portela effectively reduced osteoarthritis pain in cats and was well tolerated, including in those with early-stage kidney disease [4] - Zoetis operates as the world's largest animal health company, focusing on advancing care for animals and supporting animal well-being across both companion and livestock markets [5]